Prime Capital Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Prime Capital Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,868	Closed	-$236K	–	932
2024 Q2	$236K	Sell	2,868 -2,145	-43%	-$179K	﹤0.01%	802
2024 Q1	$438K	Sell	5,013 -3,957	-44%	-$354K	0.01%	655
2023 Q4	$865K	Sell	8,970 -241	-3%	-$21.3K	0.01%	458
2023 Q3	$815K	Buy	9,211 +2,204	+31%	+$196K	0.02%	377
2023 Q2	$607K	Buy	7,007 +200	+3%	+$18.8K	0.01%	438
2023 Q1	$662K	Buy	+6,807	New	+$706K	0.03%	302

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Prime Capital Investment Advisors's BMRN Position: Q3 2024 in Review

Prime Capital Investment Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 2,868 shares — an estimated $236K sold.

Prime Capital Investment Advisors first reported a position in BMRN in Q1 2023 and held it in 6 quarters. The position peaked at $865K in Q4 2023. 554 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

Prime Capital Investment Advisors reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Prime Capital Investment Advisors sold 2,868 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $236K.
Prime Capital Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2023 and held it in 6 quarters.
Prime Capital Investment Advisors's BioMarin Pharmaceuticals position peaked at $865K in Q4 2023.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on Prime Capital Investment Advisors's 13F filing for Q3 2024, filed 5 Nov 2024.